John Jones
· Associate Professor and Director of Digital Media StudiesOhio State University · English
Active 1993–2024
Academic metrics are sourced from OpenAlex and public funding records; values may differ from Google Scholar.
About
John Jones is an Associate Professor and the Director of Digital Media Studies at The Ohio State University Department of English. His primary areas of expertise include digital media studies, rhetoric, professional and technical communication, visual rhetoric, and digital humanities. Jones earned his MA in Rhetoric and Writing Studies from the University of Tennessee at Chattanooga and his PhD in English from the University of Texas at Austin. His research investigates the relationship between printing and knowledge-creation, the revision practices of Wikipedia editors, and the connections between writing and network structures. Currently, he is working on projects exploring the effects of computational processes on writing and rhetoric, particularly as they relate to wearable devices and digital culture.
Research topics
- Medicine
- Oncology
- Internal medicine
- Gastroenterology
- Immunology
- Cancer research
Selected publications
Blood · 2018-02-02 · 387 citations
articleOpen access, it was 51, 26, and 43 months, respectively, demonstrating long-term efficacy of ibrutinib in some high-risk subgroups. Survival outcomes were less robust for R/R patients with del(17p) and those who received more prior therapies. The onset of grade ≥3 cytopenias, such as neutropenia and thrombocytopenia, decreased over time. Treatment--limiting adverse events were more frequent during the first year compared with subsequent periods. These results demonstrate sustained efficacy and acceptable t…
The Lancet Oncology · 2017-12-12 · 376 citations
articleOpen access1st authorClinical Cancer Research · 2018-06-12 · 160 citations
articleOpen accessAbstract Purpose: The oral BCL-2 inhibitor venetoclax is an effective therapy for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), including disease with high-risk genomic features such as chromosome 17p deletion [del(17p)] or progressive disease following B-cell receptor pathway inhibitors. Patients and Methods: We conducted a comprehensive analysis of the safety of 400 mg daily venetoclax monotherapy in 350 patients with CLL using an integrated dataset from three pha…
Blood · 2018-01-05 · 132 citations
articleOpen accessB-cell receptor pathway inhibitors (BCRis) have transformed treatment of chronic lymphocytic leukemia (CLL); however, the efficacy of therapies for patients whose disease is refractory to/relapses after (R/R) BCRis is unknown. Venetoclax is a selective, orally bioavailable BCL-2 inhibitor with activity in patients with CLL, including those who are heavily pretreated or have 17p deletion. This phase 2 study prospectively evaluated venetoclax in patients with R/R CLL after ibrutinib or idelalisib;…
Journal of Clinical Oncology · 2020 · 103 citations
PURPOSE: The development of highly effective targeted agents for chronic lymphocytic leukemia offers the potential for fixed-duration combinations that achieve deep remissions without cytotoxic chemotherapy. PATIENTS AND METHODS: This phase II study tested a combination regimen of obinutuzumab, ibrutinib, and venetoclax for a total of 14 cycles in both patients with treatment-naïve (n = 25) and relapsed or refractory (n = 25) chronic lymphocytic leukemia to determine the response to therapy and…
Frequent coauthors
- 235 shared
John C. Byrd
University of Cincinnati
- 174 shared
Leslie A. Andritsos
New Mexico Cancer Center
- 144 shared
Kami J. Maddocks
The Ohio State University
- 129 shared
Nyla A. Heerema
St. Jude Children's Research Hospital
- 118 shared
Joseph M. Flynn
University of Bath
- 105 shared
Natarajan Muthusamy
The Ohio State University
- 84 shared
Richard R. Furman
Cornell University
- 84 shared
Kristie A. Blum
Emory University
Similar researchers at Ohio State University
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with John Jones
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup